Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
30 May 2024

ORYZON to provide corporate progress updates at several events in June

29 May 2024

ORYZON selected as Associated Partner in the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

28 June 2024

Annual General Shareholders’ Meeting 2024

Madrid

Spain

28-30 May 2024

Foro Medcap BME 2024

Madrid Stock Exchange Palace

Madrid

Spain

16 May 2024

RSC Hot Topics: Covalent Drug Discovery 2024

15 May 2024

Asebio Investor Day 2024

Kursaal Elkargunea Center, San Sebastián

Guipúzcoa

Spain

12-14 May 2024

Bio-Equity Europe 2024

Kursaal Elkargunea Center, San Sebastián

Guipúzcoa

Spain

9 May 2024

ORYZON to provide corporate progress updates at several events in May

6 May 2024

ORYZON reports financial results and corporate update for quarter ended March 31, 2024

22 April 2024

ORYZON secures another important patent for its lead CNS asset, vafidemstat

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel